FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

/ashington,	D.C.	20549
vasimigton,	D.O.	20070

Check this box if no longer subject
to Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1/h)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per response:	0.5							

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Neufeld Leah R				2. Issuer Name and Ticker or Trading Symbol Immuneering Corp [IMRX]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title Other (specify								
(Last) 245 MA	`	First	t) (N	/liddle)		3. Date of Earliest Transaction (Month/Day/Year) 03/15/2024							X	belov	Officer (give title below) CHIEF PEOPLE OF		below)			
SECOND FLOOR					4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)							
(Street)	IDGE 1	MA	0.	2142											X	X Form filed by One Reporting Person Form filed by More than One Reportin Person				
(City)	(Stat	e) (Z	ľip)		Rule 10b5-1(c) Transaction Indication														
						Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is inte satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.								nded to						
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3) 2. Transact Date (Month/Day					y/Year) Execution		ition Date,				s Acquired (A) of (D) (Instr. 3, 4			5. Amo Securi Benefi Owned Report	ties cially I Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount	(A) o (D)	r Pri	се	Transa	ction(s) 3 and 4)			(111511.4)	
Class A Common Stock ⁽¹⁾ 03/15/20					03/15/20)24 ⁽²⁾			A		6,211	A	\$	1.62(3)	6	5,211 D		D		
Class A Common Stock 03/20/2					2024			P		3,818	A	\$2	2.8793	1	0,029		D			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	Derivative Conversion Date Execution Date, Gecurity or Exercise (Month/Day/Year) if any				Transaction Code (Instr. 8)		5. Nu of Deriv Secu Acqu (A) or Dispo of (D) (Instr	rities ired r osed : 3, 4	6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Inst 3 and 4)		De Se (In	Price of rivative curity str. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	y	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
						Code V		(A)	(D)	Date Exercisable		Expiration Date	Title	Amou or Numb of Share	er					

Explanation of Responses:

- 1. The reporting person is voluntarily reporting the acquisition of shares of the issuer's Class A Common Stock pursuant to the Immuneering Corporation 2021 Employee Stock Purchase Plan (the "ESPP"), for the ESPP purchase period of September 15, 2023 through March 15, 2024. This transaction is also exempt pursuant to Rule 16b-3(c) promulgated pursuant to the Securities Exchange Act of
- 2. The relevant Offering Period (as defined in the ESPP) ended, and the shares were acquired, on the Purchase Date (as defined in the ESPP) of March 15, 2024.
- 3. In accordance with the ESPP, the shares were purchased at a price not less than eighty-five percent (85%) of the Fair Market Value (as defined in the ESPP) of a share of Class A Common Stock on the Purchase Date of March 15, 2024.

Remarks:

/s/ Michael D. Bookman, 03/21/2024 Attorney-in-Fact for Leah R. Neufeld

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.